Biohaven Ltd. $BHVN Shares Acquired by Prosight Management LP

Prosight Management LP increased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 11.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,000 shares of the company’s stock after purchasing an additional 60,929 shares during the period. Biohaven accounts for about 2.1% of Prosight Management LP’s investment portfolio, making the stock its 20th largest holding. Prosight Management LP’s holdings in Biohaven were worth $9,006,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BHVN. Integral Health Asset Management LLC increased its position in shares of Biohaven by 116.7% during the 3rd quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $9,756,000 after purchasing an additional 350,000 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Biohaven by 34.2% in the third quarter. BNP Paribas Financial Markets now owns 843,564 shares of the company’s stock valued at $12,662,000 after buying an additional 214,942 shares during the period. Capital Research Global Investors lifted its holdings in shares of Biohaven by 108.9% in the third quarter. Capital Research Global Investors now owns 1,011,530 shares of the company’s stock valued at $15,183,000 after buying an additional 527,337 shares during the period. Swiss National Bank boosted its stake in Biohaven by 1.1% during the third quarter. Swiss National Bank now owns 168,300 shares of the company’s stock valued at $2,526,000 after buying an additional 1,800 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in Biohaven during the third quarter valued at about $407,000. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Down 3.4%

Shares of NYSE:BHVN opened at $9.57 on Friday. The firm has a 50 day simple moving average of $11.50 and a 200 day simple moving average of $12.45. Biohaven Ltd. has a 52 week low of $7.48 and a 52 week high of $31.18. The company has a debt-to-equity ratio of 4.59, a quick ratio of 3.18 and a current ratio of 3.18. The company has a market cap of $1.01 billion, a PE ratio of -1.37 and a beta of 1.15.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.01. As a group, research analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on BHVN. TD Cowen boosted their price target on shares of Biohaven from $15.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Biohaven in a research report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Biohaven in a research note on Tuesday, November 18th. William Blair reiterated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.93.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.